



European Partnership for Personalised Medicine calling for national and regional involvement

An information event by ICPerMed and ERA PerMed

May 31, 2021





Personalised Medicine Stakeholder

Community

Maria Josè Ruiz Alvarez, Italian Ministry of Health (Member of ICPerMed/ERA PerMed Preparatory Group)



Personalised Medicine Partnership: our vision


 The partnership will create the synergies needed for the integration of all essential expertise in PM from the Stakeholders community

 The partnership will be inclusive and encourage the participation from all European countries and international organisations, including countries with small research communities and different advancements in PM

Stakeholders to be Involved in EP PerMed

- Stakeholders can include Industries, universities, research organisations, bodies with a public service mission at local, regional, national or international level or civil society organisations including foundations and NGOs (*Article 2 of the Horizon Europe Regulation*).
- Existing networks from the ICPerMed, ERA PerMed and the ICPerMed CSA Family could provide the basis for building this Partnership.

Personalised Medicine Stakeholder Community



How could the PM community be involved?

Suggested by ICPerMed/ERA PerMed:

- EP PerMed **MEMBERS** (GA, work actively, budget commitment)
- EP PerMed PARTNERS (Lol, monitor, support)
 - ministries, public and private 'not-for-profit' health research funding, policy organisations and healthcare institutions
- STAKEHOLDER GROUPS (dedicated groups, observer status)



When could the PM community be involved?

 ICPerMed and ERA PerMed suggest that this so-called "stakeholder community" needs to be involved from the starting phase and will be crucial as support for the successful development and implementation of PM approaches

 They should be able to collaborate from the identification of challenges and opportunities to the alignment on regional, national, European and international levels with complementary access to resources, information and data

Participation: what are the benefits?

- Researchers across European countries and regions <u>could</u> <u>enhance collaborative research</u> on PM and <u>achieve</u> <u>transnational collaborations in research funding; International</u> <u>collaboration</u> can <u>consolidate</u> the research beyond the EU;
- Health and care authorities, policymakers and other stakeholders could develop <u>evidence-based strategies</u> and policies on PM
 - <u>Learn from good practices</u> on PM of European countries and regions, but also of non-European countries;
 - <u>achieve alignments</u> on the strategic level as well as the <u>increase of resources</u>
 - could <u>apply new strategies</u> on how to plan and carry out efficient investments in PM at national/regional level;


The benefits of Participation

- Researchers, policymakers and other stakeholders should <u>use</u> widely-disseminated research results based on <u>Open Science</u> principles;
- Healthcare providers and professionals should be assisted in order to improved their knowledge on how to implement PM approaches;
- Innovators and all types of local/regional private stakeholders could join and this might <u>facilitate</u> the uptake of <u>successful</u> innovations;
- Citizens and health and care professionals would be able to improve their PM literacy to better understand and apply PM approaches;
- Patients, citizens and society as a whole could participate and play an active role in the PM implementation



Participation Role

 Obviously, the role of every actor may be based on their functional role such as activities involving policy, funding research and support or consultation; under the overall goal of the PM implementation



Overall goal: PM implementation

Stakeholder Community: conclusions

- The cooperation of all stakeholders might facilitate consensusbuilding and decision-making processes in the implementation of the research PM outcome into the health systems. Always considering the upcoming needs.
- The involvement of different kinds of organisations as members, partners or stakeholders, is needed to achieve a flexible framework for cooperation and efficient execution of the proposed work programme, at the operational level.



Thank you for your attention!

Contact details of the ICPerMed/ERA PerMed preparatory group:

ICPerMed: <u>ICPerMed@dlr.de</u>

• ERA PerMed: ERA PerMed: ERAPerMed@agencerecherche.fr